{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T17:02:30Z","timestamp":1795280550998,"version":"4.10.3"},"reference-count":30,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2021,11,2]]},"DOI":"10.1080\/17425247.2021.1968826","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T22:58:47Z","timestamp":1628895527000},"page":"1571-1576","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":31,"title":["Port delivery system: a novel drug delivery platform to treat retinal diseases"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-5599","authenticated-orcid":false,"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[{"name":"Sierra Eye Associates, Reno, NV, USA"},{"name":"University of Nevada, Reno School of Medicine, Reno, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-4861","authenticated-orcid":false,"given":"Aamir A.","family":"Aziz","sequence":"additional","affiliation":[{"name":"Sierra Eye Associates, Reno, NV, USA"},{"name":"University of Nevada, Reno School of Medicine, Reno, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1894-4267","authenticated-orcid":false,"given":"Weijie Violet","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Harkness Eye Institute, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordyn","family":"Vannavong","sequence":"additional","affiliation":[{"name":"Sierra Eye Associates, Reno, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1772-3558","authenticated-orcid":false,"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, UPMC Eye Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Danzig","sequence":"additional","affiliation":[{"name":"Rand Eye Institute, Deerfield Beach, FL, USA"},{"name":"Florida Atlantic University, Boca Raton, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-045X","authenticated-orcid":false,"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.005"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2519-x"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00248"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.107"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S169143"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.09.009"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13085"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.10.010"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-313991"},{"key":"cit0011","unstructured":"Genetech. Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration. 2020. [cited 1 Jun 2020]. gene.com"},{"key":"cit0012","unstructured":"Cimberle M. Strategies for sustained anti-VEGF delivery aimed at consistent dosing, durability.\n                      Helio News\n                      . 2020. [cited 1 Jun 2020]. Helio.com"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.036"},{"key":"cit0014","author":"Kirkner RM","year":"2020","journal-title":"Retina Specialist"},{"key":"cit0015","author":"Pieramici DJ","year":"2019","journal-title":"Retin Physician"},{"key":"cit0016","author":"Loewenstein A","year":"2020","journal-title":"ARVO Annual Meeting: Investigative Ophthalmology & Visual Science"},{"key":"cit0017","unstructured":"Seminara L. Ranibizumab Port Delivery System for AMD: phase 2. EyeNet Magazine. 2019."},{"key":"cit0018","author":"Hopkins JJ","year":"2016","journal-title":"ARVO Annual Meeting: Investigative Ophthalmology & Visual Science"},{"key":"cit0019","author":"Khanani AM","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"cit0020","unstructured":"Khanani AM, Gune S, Maia M, et al. Pharmacokinetic (PK) Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 2 Ladder Trial. In: 20th EURETINA Congress. Netherlands: Amsterdam, Noord Holland; 2020."},{"key":"cit0021","unstructured":"Roche\u2019s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration. Basel, Switzerland: GlobeNewswire 2020."},{"key":"cit0022","author":"Campochiaro PA","year":"2020","journal-title":"American Society of Retina Specialists Annual Meeting"},{"key":"cit0023","first-page":"2020","volume":"1","author":"Khanani AM","year":"2020","journal-title":"MedEdicus"},{"key":"cit0024","unstructured":"Bagheri N, Chiang A, Avery RL, et al. The AMD Pipeline: a Look at the Latest Results.\n                      Retina Today\n                      : Retina Today 2020."},{"key":"cit0025","unstructured":"Pieramici DJ, Gune S, Maia M, et al. Pharmacokinetic Profile of the Port Delivery System With Ranibizumab (PDS) in the Phase 3 Archway Trial. Macular Society. 2021."},{"key":"cit0026","unstructured":"Mahler K, Highlights ASRS 2020. Roche Analyst Webcast; 2020; San Francisco; 2020."},{"key":"cit0027","unstructured":"Roche H-L.\u00a0Extension Study for the Port Delivery System With Ranibizumab (Portal).\u00a02021.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03683251"},{"key":"cit0028","unstructured":"Roche H-L. This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With\u00a0515\u00a0Intravitreal Ranibizumab (Pagoda).\u00a02021.\u00a0Available from: https:\/\/ clinicaltrials.gov\/ct2\/show\/NCT04108156"},{"key":"cit0029","unstructured":"Roche H-L, Multicenter A. Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION). 2021. [cited 1 Jun 2020]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04503551"},{"key":"cit0030","first-page":"36","volume":"17","author":"Siddiqui FA, Aziz, AA, Khanani, AM.\u00a0","year":"2020","journal-title":"Retin Physician"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2021.1968826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T09:23:10Z","timestamp":1635844990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2021.1968826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,2]]}},"alternative-id":["10.1080\/17425247.2021.1968826"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2021.1968826","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}